# Lorcaserin × Cardiovascular event superiority (MACE+) — Evidence checklist Verdict 2950 · Evidence Check Stored-material review date: Not recorded Original evidence cut-off: 2026-08-26 Review-criteria version: 1.0 Public page/material preparation date: 2026-10-11 Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect. ## Assessment scope - Population: Patients with overweight/obesity in the CAMELLIA citation context; exact age, baseline risk and eligibility criteria unverified - Ingredient, formulation and route: Original long-term lorcaserin (Belviq) trial intervention - Dose: Actual formulation, dose and frequency absent from the original summary and unverified; not medication/usage instructions - Comparator: Double-blind placebo control; placebo composition and shared care/accompanying treatment unverified - Measured outcome: Cardiovascular efficacy MACE+ superiority; MACE safety noninferiority, weight and cancer harms are separate context - Duration: CAMELLIA median follow-up 3.3 years; endpoint-specific event windows and individual follow-up durations unverified - Questions outside this scope: Establishing cardiovascular superiority from weight response; Using MACE noninferiority to resolve MACE+ superiority, cancer or all harms; Converting nonsignificance to zero effect or equivalence; Efficacy or safety of other drugs or the class; Verification of current marketing/authorization status, permission to take the drug or treatment instructions ## Checklist items ### N01 · Is the selected question cardiovascular event superiority? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The preserved subclaim wording is “Cardiovascular event superiority”. MACE+ efficacy results are linked separately from the parent long-term weight-loss and lorcaserin context. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The final independent-claim count is not established. - Reason for missing information: The final count of independent claims remains undetermined. - Required materials and conditions: Links between the selected subclaim, parent and MACE+ results - Materials to obtain first: Links between the selected subclaim, parent and MACE+ results - Further research: If the question actually changes, record the original question and excluded scope separately. - Conditions for verification: Preserve exact existing wording and question/verdict records separately. - Why this condition is needed: A condition for separately recording original information and gaps for: Is the selected question cardiovascular event superiority? - Application exceptions: Do not create new questions, hypothetical main questions or splits. - Remaining uncertainty: Do not create new questions, hypothetical main questions or splits. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M03 §3.2.4; our own extension boundary - Related sources: R01 ### N02 · Are subclaim grade D and its note separated from parent grade C and 50 points? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Subclaim grade D and “MACE+ was null, HR 0.97, P=0.55” are preserved. Subclaim score, status and axes keys are absent and left null. The parent weight evidence has grade C, 50 points and a safety warning. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No subclaim-specific score, status or axes are present in the source. - Reason for missing information: The original record has no subclaim-specific score, status or axes. - Required materials and conditions: Original locations of actual and absent subclaim fields and the parent verdict - Materials to obtain first: Original locations of actual and absent subclaim fields and the parent verdict - Further research: If subclaim fields are actually added, separate the original version and change in a new event. - Conditions for verification: Retain the distinct verdict scope of selected subclaim values and the parent. - Why this condition is needed: A condition for separately recording original information and gaps for: Are subclaim grade D and its note separated from parent grade C and 50 points? - Application exceptions: Do not fill subclaim-specific values with parent C50/E+/S/I0. - Remaining uncertainty: Do not fill subclaim-specific values with parent C50/E+/S/I0. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design - Related sources: R01 ### N03 · Are parent axes, cross-checking and the grade decision current verification? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The parent’s surrogate endpoint, manufacturer-only evidence, noninferiority design, cross-checking and R1/I0/E+ are existing weight-verdict history. They are not a new clinical review or grade for this cardiovascular sheet. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No current RoB2 assessment, methodology certification or evidence reassessment was performed. - Reason for missing information: No current RoB2 assessment, methodology certification or evidence reassessment was performed. - Required materials and conditions: Parent Korean and English text, axes, synthesis and verdict/correction history - Materials to obtain first: Parent Korean and English text, axes, synthesis and verdict/correction history - Further research: Record subsequent evidence updates as separate events within the user’s requested scope. - Conditions for verification: Preserve original verdict history while leaving current review of the existing content incomplete. - Why this condition is needed: A condition for separately recording original information and gaps for: Are parent axes, cross-checking and the grade decision current verification? - Application exceptions: Do not repurpose parent endpoint S or the false large hard-endpoint RCT flag as new classification or review of the selected cardiovascular endpoint. - Remaining uncertainty: Do not repurpose parent endpoint S or the false large hard-endpoint RCT flag as new classification or review of the selected cardiovascular endpoint. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M08 §8.1–8.2.3; our own application - Related sources: R01 ### N04 · At what material level did actual reading occur? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The entire designated source summary and selected unit were read for production. External abstracts, full text, FDA communications, registrations and protocols were neither read nor accessed. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. External content is unread, with access not attempted. - Reason for missing information: External content is unread, with access not attempted. - Required materials and conditions: Acquisition and reading scope for the stored summary and each external material - Materials to obtain first: Acquisition and reading scope for the stored summary and each external material - Further research: If material or reading history is supplied, record the actual reading level of the corresponding slot. - Conditions for verification: Mark local material as summary read and external material as unread. - Why this condition is needed: A condition for separately recording original information and gaps for: At what material level did actual reading occur? - Application exceptions: Do not convert a URL’s presence to full-text acquisition, link verification or access failure. - Remaining uncertainty: Do not convert a URL’s presence to full-text acquisition, link verification or access failure. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5–4.6 material-collection and selection principles; separation of access and reading and hyperlink rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design - Related sources: R01, R02, R03, R04, R05 ### N05 · How are trials, regulatory reanalysis, reports and weight trials connected? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original CAMELLIA trial, FDA cancer reanalysis of the same trial, the paper and communication describing the FDA review, BLOOM and the maintenance trial are distinguished. FDA reanalysis is not a separate efficacy trial. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Unique-trial and participant totals and current independent replication are not established. - Reason for missing information: Unique-trial and participant totals and current independent replication are not established. - Required materials and conditions: Relationships among citations, registrations, reports, trials and populations - Materials to obtain first: Relationships among citations, registrations, reports, trials and populations - Further research: If original lists are supplied, record links between the same family and separate reports. - Conditions for verification: Distinguish report-entry counts from unestablished unique-trial and population counts. - Why this condition is needed: A condition for separately recording original information and gaps for: How are trials, regulatory reanalysis, reports and weight trials connected? - Application exceptions: Do not add people, cancer events or regulatory documents from the same CAMELLIA trial as new trials or participants. - Remaining uncertainty: Do not add people, cancer events or regulatory documents from the same CAMELLIA trial as new trials or participants. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort and outcome linking is our own application / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application - Related sources: R01, R02, R03, R04, R05 ### N06 · Who were the actual CAMELLIA participants? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The citation title concerns cardiovascular safety in patients with overweight or obesity. The original summary includes 12,000 participants but does not detail age, baseline cardiovascular risk or eligibility/exclusion criteria. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Exact age, baseline risk and eligibility criteria are unverified. - Reason for missing information: Exact age, baseline risk and eligibility criteria are unverified. - Required materials and conditions: Participant age, diseases/risks, eligibility/exclusion and baseline characteristics - Materials to obtain first: Participant age, diseases/risks, eligibility/exclusion and baseline characteristics - Further research: If original participant tables are supplied, distinguish the selected population and generalization scope. - Conditions for verification: Retain the original participant wording and gaps in detailed selection conditions. - Why this condition is needed: A condition for separately recording original information and gaps for: Who were the actual CAMELLIA participants? - Application exceptions: Do not certify event effects for all adults or all patients with obesity from a citation title alone. - Remaining uncertainty: Do not certify event effects for all adults or all patients with obesity from a citation title alone. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design - Related sources: R01 ### N07 · What were the actual lorcaserin formulation, amount and duration of use? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original context of long-term lorcaserin (Belviq) use and a serotonin 2C receptor agonist for weight loss is preserved. Actual dose, formulation and dosing frequency are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Formulation, dose, frequency and actual adherence/duration of use are unverified. - Reason for missing information: Formulation, dose, frequency and actual adherence/duration of use are unverified. - Required materials and conditions: Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records - Materials to obtain first: Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records - Further research: If original intervention records are supplied, distinguish nominal and actual exposure and duration. - Conditions for verification: Separate the original intervention name from gaps in actual exposure details. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the actual lorcaserin formulation, amount and duration of use? - Application exceptions: Do not create medication instructions or doses absent from the source. - Remaining uncertainty: Do not create medication instructions or doses absent from the source. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application - Related sources: R01 ### N08 · What were the placebo and accompanying lifestyle care or medications? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: CAMELLIA is preserved as a double-blind, placebo-controlled trial. Placebo formulation, shared lifestyle interventions and the content and balance of accompanying cardiovascular/diabetes treatment are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Placebo composition, accompanying treatment and lifestyle content are unverified. - Reason for missing information: Placebo composition, accompanying treatment and lifestyle content are unverified. - Required materials and conditions: Placebo characteristics, shared care, accompanying medications and baseline changes - Materials to obtain first: Placebo characteristics, shared care, accompanying medications and baseline changes - Further research: If original comparator and accompanying-intervention material is supplied, record actual between-group differences and shared exposure. - Conditions for verification: Separate the original comparator type from unverified specific comparison conditions. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the placebo and accompanying lifestyle care or medications? - Application exceptions: Do not convert placebo control to a no-care or no-treatment comparison. - Remaining uncertainty: Do not convert placebo control to a no-care or no-treatment comparison. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application / M19 §19.2.2–19.2.4 design considerations; detailed confounding records are our own design - Related sources: R01 ### N09 · What were the original randomization size and follow-up duration? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: CAMELLIA allocated 12,000 participants in groups of 6,000, with median follow-up of 3.3 years. These describe the original allocation size and median follow-up. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis/follow-up denominators and individual follow-up durations are unverified. - Reason for missing information: Actual endpoint-specific analysis/follow-up denominators and individual follow-up durations are unverified. - Required materials and conditions: Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows - Materials to obtain first: Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows - Further research: If original flow/follow-up tables are supplied, record the roles of each denominator and duration. - Conditions for verification: Record allocation denominators and median follow-up separately from actual endpoint-specific denominators. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the original randomization size and follow-up duration? - Application exceptions: Do not make median 3.3-year follow-up the same follow-up time for every participant. - Remaining uncertainty: Do not make median 3.3-year follow-up the same follow-up time for every participant. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M08 §8.1–8.2.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design - Related sources: R01 ### N10 · What were the components and event definitions of the MACE+ efficacy endpoint? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary labels MACE+ as the primary efficacy endpoint. Individual composite components, first/repeated events and confirmation criteria are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. MACE+ components and adjudication criteria are unverified. - Reason for missing information: MACE+ components and adjudication criteria are unverified. - Required materials and conditions: MACE+ components, event adjudication, repeated/first events and endpoint definitions - Materials to obtain first: MACE+ components, event adjudication, repeated/first events and endpoint definitions - Further research: If original plans/result tables are supplied, separate the composite endpoint and each component event. - Conditions for verification: Preserve the original MACE+ name and leave specific components unverified. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the components and event definitions of the MACE+ efficacy endpoint? - Application exceptions: Do not fill in guessed conventional MACE definitions or components from other material. - Remaining uncertainty: Do not fill in guessed conventional MACE definitions or components from other material. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M03 §3.2.4; our own application - Related sources: R01 ### N11 · What were the original MACE+ event counts, percentages and denominators? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary records MACE+ in 707 lorcaserin participants (11.8%) versus 727 placebo participants (12.1%). Allocation counts of 6,000/6,000 are preserved separately. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Endpoint-specific analysis denominators, repeated-event handling and at-risk population details are unverified. - Reason for missing information: Endpoint-specific analysis denominators, repeated-event handling and at-risk population details are unverified. - Required materials and conditions: People with events/event counts, at-risk population and endpoint analysis denominators - Materials to obtain first: People with events/event counts, at-risk population and endpoint analysis denominators - Further research: If original event/flow tables are supplied, record whether each value concerns people, repeated events or an analysis denominator. - Conditions for verification: Retain original people/percentages and allocation denominators unchanged. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the original MACE+ event counts, percentages and denominators? - Application exceptions: Do not recalculate original percentages or add the two arms or events together. - Remaining uncertainty: Do not recalculate original percentages or add the two arms or events together. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design - Related sources: R01 ### N12 · What were the MACE+ HR, interval and P value? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: MACE+ HR 0.97 (0.87~1.07), P=0.55 is preserved. The confidence level of the MACE+ interval is not separately specified in that original summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The MACE+ interval confidence level, model and adjustments were not directly checked. - Reason for missing information: The MACE+ interval confidence level, model and adjustments were not directly checked. - Required materials and conditions: Estimation model, interval confidence level, adjustments and effect of interest - Materials to obtain first: Estimation model, interval confidence level, adjustments and effect of interest - Further research: If original analysis methods/result tables are supplied, record the definitions of the original HR and interval. - Conditions for verification: Preserve original MACE+ HR, interval and P value at each originally stated level. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the MACE+ HR, interval and P value? - Application exceptions: Do not automatically copy the explicit MACE 95% level to the MACE+ interval or calculate new HRs/CIs. - Remaining uncertainty: Do not automatically copy the explicit MACE 95% level to the MACE+ interval or calculate new HRs/CIs. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M15 §15.3.1–15.3.3; our own application - Related sources: R01 ### N13 · Does null superiority mean zero effect or equivalence? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The subclaim note and parent describe the MACE+ superiority result as null. The original HR 0.97 (0.87~1.07), P=.55 is retained without a new zero-effect or equivalence verdict. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified superiority-analysis details and the clinical-importance threshold are unverified. - Reason for missing information: Prespecified superiority-analysis details and the clinical-importance threshold are unverified. - Required materials and conditions: Prespecified superiority hypothesis, analysis plan and original uncertainty - Materials to obtain first: Prespecified superiority hypothesis, analysis plan and original uncertainty - Further research: If original plans are supplied, distinguish the superiority hypothesis from actual estimates and uncertainty. - Conditions for verification: Preserve the original null-result description together with the uncertainty interval. - Why this condition is needed: A condition for separately recording original information and gaps for: Does null superiority mean zero effect or equivalence? - Application exceptions: Do not convert nonsignificance to zero event difference, equivalence or a personal safety guarantee. - Remaining uncertainty: Do not convert nonsignificance to zero event difference, equivalence or a personal safety guarantee. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M15 §15.3.1–15.3.3; Chamgap adaptation - Related sources: R01 ### N14 · Are the MACE cardiovascular safety results preserved separately? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary records the MACE safety endpoint in 364 participants (6.1%) versus 369 (6.2%), HR 0.99 (95% CI 0.85~1.14). It is a different endpoint from MACE+ efficacy superiority. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Detailed MACE components, analysis denominators and model are unverified. - Reason for missing information: Detailed MACE components, analysis denominators and model are unverified. - Required materials and conditions: MACE definitions, denominators, model and original safety estimates - Materials to obtain first: MACE definitions, denominators, model and original safety estimates - Further research: If original safety methods/result tables are supplied, link MACE and MACE+ separately. - Conditions for verification: Keep original MACE safety values separate from MACE+ efficacy values. - Why this condition is needed: A condition for separately recording original information and gaps for: Are the MACE cardiovascular safety results preserved separately? - Application exceptions: Do not repurpose MACE numbers/CIs as MACE+ efficacy results. - Remaining uncertainty: Do not repurpose MACE numbers/CIs as MACE+ efficacy results. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is our own design - Related sources: R01 ### N15 · To which endpoint does the HR 1.40 noninferiority margin apply? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary states that the prespecified HR 1.40 margin for MACE cardiovascular safety noninferiority was met. Original registration/plan text remains unread. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original planned basis and analysis conditions for the prespecified margin were not directly read. - Reason for missing information: The original planned basis and analysis conditions for the prespecified margin were not directly read. - Required materials and conditions: Planned basis for the noninferiority margin, applicable endpoint and analysis population - Materials to obtain first: Planned basis for the noninferiority margin, applicable endpoint and analysis population - Further research: If original plans are supplied, distinguish the margin’s definition at the time and the reported results. - Conditions for verification: Link the original margin, applicable MACE endpoint and unread external plans. - Why this condition is needed: A condition for separately recording original information and gaps for: To which endpoint does the HR 1.40 noninferiority margin apply? - Application exceptions: Do not use HR 1.40 as a threshold for MACE+ superiority, cancer safety or overall harmlessness. - Remaining uncertainty: Do not use HR 1.40 as a threshold for MACE+ superiority, cancer safety or overall harmlessness. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation - Related sources: R01 ### N16 · Are the safety/efficacy endpoint hierarchy and testing order known? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary explicitly labels MACE as the primary safety endpoint and MACE+ as the primary efficacy endpoint. Hierarchical testing order, alpha allocation and the hierarchy of additional endpoints are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual hierarchy, multiplicity and testing order are unverified. - Reason for missing information: Actual hierarchy, multiplicity and testing order are unverified. - Required materials and conditions: Endpoint hierarchy, testing order, multiplicity and change records - Materials to obtain first: Endpoint hierarchy, testing order, multiplicity and change records - Further research: If the original SAP/registration is supplied, record the prespecified relationship between safety noninferiority and efficacy superiority. - Conditions for verification: Distinguish original endpoint roles and unverified hierarchy details. - Why this condition is needed: A condition for separately recording original information and gaps for: Are the safety/efficacy endpoint hierarchy and testing order known? - Application exceptions: Do not promote the two primary-endpoint labels to direct certification of all testing procedures. - Remaining uncertainty: Do not promote the two primary-endpoint labels to direct certification of all testing procedures. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design - Related sources: R01 ### N17 · Are composite and individual cardiovascular events distinguished? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The MACE and MACE+ composite names and original aggregations are preserved. Effects, denominators and CIs for individual components are absent from the summary. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct values for death and individual cardiovascular events and overlap among components are unverified. - Reason for missing information: Direct values for death and individual cardiovascular events and overlap among components are unverified. - Required materials and conditions: Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events - Materials to obtain first: Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events - Further research: If individual-event tables are supplied, separate direct results for the overall composite and each component. - Conditions for verification: Retain the boundary between composite endpoints and unverified individual clinical outcomes. - Why this condition is needed: A condition for separately recording original information and gaps for: Are composite and individual cardiovascular events distinguished? - Application exceptions: Do not copy a composite HR as every individual-event HR or mortality benefit. - Remaining uncertainty: Do not copy a composite HR as every individual-event HR or mortality benefit. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M03 §3.2.4; our own extension boundary - Related sources: R01 ### N18 · What was the actual cardiovascular analysis observation window? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Median follow-up of 3.3 years is preserved context for CAMELLIA overall. Actual MACE/MACE+ event-aggregation windows, follow-up after discontinuation and censoring times are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Cardiovascular endpoint-specific time definitions and censoring are unverified. - Reason for missing information: Cardiovascular endpoint-specific time definitions and censoring are unverified. - Required materials and conditions: Endpoint-specific start/end times, follow-up after discontinuation and censoring - Materials to obtain first: Endpoint-specific start/end times, follow-up after discontinuation and censoring - Further research: If original follow-up/analysis records are supplied, distinguish median follow-up and actual event windows. - Conditions for verification: Separate original duration descriptions from endpoint-specific timing gaps. - Why this condition is needed: A condition for separately recording original information and gaps for: What was the actual cardiovascular analysis observation window? - Application exceptions: Do not replace all event windows with the one-year weight time point or median 3.3 years. - Remaining uncertainty: Do not replace all event windows with the one-year weight time point or median 3.3 years. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design - Related sources: R01 ### N19 · What were the HR effect of interest, censoring and competing-risk treatment? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: Original HRs are supplied, but proportional-hazards assumptions, ITT/actual-use estimands, censoring, competing risks and adjusted models are absent from the summary. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. HR models, effects of interest and competing-risk/censoring handling are unverified. - Reason for missing information: HR models, effects of interest and competing-risk/censoring handling are unverified. - Required materials and conditions: Effect of interest, statistical model, censoring/competing events and sensitivity analyses - Materials to obtain first: Effect of interest, statistical model, censoring/competing events and sensitivity analyses - Further research: If original methods/SAPs are supplied, record the actual estimands and assumptions for each cardiovascular HR. - Conditions for verification: Separate original HRs from unverified analysis assumptions. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the HR effect of interest, censoring and competing-risk treatment? - Application exceptions: Do not interpret an HR as a simple risk ratio or individual prevention probability, or convert it to new values. - Remaining uncertainty: Do not interpret an HR as a simple risk ratio or individual prevention probability, or convert it to new values. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 §8.2.2, M15 §15.3.1; our own application / M15 §15.3.1–15.3.3; our own application / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design - Related sources: R01 ### N20 · What is the scope of blinding and cardiovascular event adjudication? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary describes CAMELLIA as double-blind and placebo-controlled. Event adjudication committees, data-collection routes and adjudication-blinding details are absent from the summary. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Role-specific blinding, independent adjudication and event-confirmation methods are unverified. - Reason for missing information: Role-specific blinding, independent adjudication and event-confirmation methods are unverified. - Required materials and conditions: Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences - Materials to obtain first: Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences - Further research: If original adjudication/methods material is supplied, record actual roles and event-collection scope. - Conditions for verification: Separate the original design label from gaps in adjudication details. - Why this condition is needed: A condition for separately recording original information and gaps for: What is the scope of blinding and cardiovascular event adjudication? - Application exceptions: Do not extend a double-blind label to certification of every outcome-adjudication or analysis process. - Remaining uncertainty: Do not extend a double-blind label to certification of every outcome-adjudication or analysis process. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M03 §3.2.4; our own application / M08 §8.1–8.2.3; our own application - Related sources: R01 ### N21 · What are the details of randomization, concealment and baseline balance? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The original scale of 12,000 participants randomized 6,000/6,000 is preserved. Sequence generation, concealment, stratification and baseline-balance details are absent from the summary. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Allocation processes, concealment and baseline balance are unverified. - Reason for missing information: Allocation processes, concealment and baseline balance are unverified. - Required materials and conditions: Allocation process, concealment, stratification and baseline-characteristic tables - Materials to obtain first: Allocation process, concealment, stratification and baseline-characteristic tables - Further research: If original allocation/baseline material is supplied, distinguish the design description from actual processes. - Conditions for verification: Keep original allocation labels separate from gaps in direct methods. - Why this condition is needed: A condition for separately recording original information and gaps for: What are the details of randomization, concealment and baseline balance? - Application exceptions: Do not declare all bias conditions satisfied from a randomized label alone. - Remaining uncertainty: Do not declare all bias conditions satisfied from a randomized label alone. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 §8.1–8.2.3; our own application / M03 §3.2.1; detailed population conditions are our own design - Related sources: R01 ### N22 · How were CAMELLIA attrition, missing data and treatment crossover handled? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: CAMELLIA allocation size and median follow-up are available, but arm-specific attrition, treatment discontinuation, crossover, missing data and analysis-population details are absent from the summary. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. CAMELLIA endpoint-specific missing-data/attrition and ITT/PP handling details are unverified. - Reason for missing information: CAMELLIA endpoint-specific missing-data/attrition and ITT/PP handling details are unverified. - Required materials and conditions: Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses - Materials to obtain first: Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses - Further research: If original flow/analysis material is supplied, distinguish allocation, use, measurement and analysis denominators. - Conditions for verification: Do not mix denominators and missing-data material across trials. - Why this condition is needed: A condition for separately recording original information and gaps for: How were CAMELLIA attrition, missing data and treatment crossover handled? - Application exceptions: Do not transfer BLOOM retention as CAMELLIA follow-up/analysis percentages. - Remaining uncertainty: Do not transfer BLOOM retention as CAMELLIA follow-up/analysis percentages. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M08 §8.2.2, M15 §15.3.1; our own application / M19 §19.1.2–19.2.4, M04 §4.6.3; our own application - Related sources: R01 ### N23 · Are people, composite events and repeated measurements different units? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Original MACE/MACE+ descriptions use people and percentages; cancer diagnoses, primary-cancer counts and weight responses use other outcome units. Events and time points from the same participants are not counted as new participants. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Event overlap, repeated-event handling and exact endpoint-specific at-risk populations are unverified. - Reason for missing information: Event overlap, repeated-event handling and exact endpoint-specific at-risk populations are unverified. - Required materials and conditions: Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes - Materials to obtain first: Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes - Further research: If original aggregation tables are supplied, record each unit and reporting relationship. - Conditions for verification: Retain original units and do not create unestablished totals. - Why this condition is needed: A condition for separately recording original information and gaps for: Are people, composite events and repeated measurements different units? - Application exceptions: Do not add counts from different endpoints/time points as independent populations or total events. - Remaining uncertainty: Do not add counts from different endpoints/time points as independent populations or total events. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation - Related sources: R01, R05 ### N24 · Were the NCT and prespecified plans actually compared? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original CAMELLIA trial and FDA reanalysis share NCT02019264. The registration identifier is preserved, but registration, protocol and SAP originals remain unread. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct content and timing of preregistration/plans are unverified. - Reason for missing information: Direct content and timing of preregistration/plans are unverified. - Required materials and conditions: Preregistration timing, endpoints/hierarchy, plan changes and analysis documents - Materials to obtain first: Preregistration timing, endpoints/hierarchy, plan changes and analysis documents - Further research: If original registration/plan material is supplied, link actual timing and prespecified definitions. - Conditions for verification: Distinguish original registration strings and the scope of unread external material. - Why this condition is needed: A condition for separately recording original information and gaps for: Were the NCT and prespecified plans actually compared? - Application exceptions: Do not count the same NCT as two independent-trial registrations or convert it to certification of prespecification. - Remaining uncertainty: Do not count the same NCT as two independent-trial registrations or convert it to certification of prespecification. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5–4.6 provide collection and selection principles; separating access from reading and the hyperlink convention are our own design / M08 Table 8.2.a, M04 §4.6.3; our own application - Related sources: R01, R05 ### N25 · Are subgroup- and duration-specific cardiovascular effects known? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The original summary contains overall MACE/MACE+ values. It lacks effect-modification results by risk, sex, comorbidities, actual exposure amount or duration. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct subgroup/duration-specific estimates and interactions are unverified. - Reason for missing information: Direct subgroup/duration-specific estimates and interactions are unverified. - Required materials and conditions: Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals - Materials to obtain first: Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals - Further research: If subgroup analyses are supplied, separate overall comparisons and subgroup interactions. - Conditions for verification: Retain gaps in direct evidence outside the overall results. - Why this condition is needed: A condition for separately recording original information and gaps for: Are subgroup- and duration-specific cardiovascular effects known? - Application exceptions: Do not copy the overall HR as an effect for specific populations, durations or optimal exposure. - Remaining uncertainty: Do not copy the overall HR as an effect for specific populations, durations or optimal exposure. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design - Related sources: R01 ### N26 · Are superiority’s clinical importance and interpretation of all outcomes the same? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original MACE+ interval and P=.55 are preserved. The superiority result is not extended to guaranteed cardiovascular-event improvement, equivalence or a single conclusion about all benefits/risks. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified MACE+ clinical-importance criteria and direct absolute effects/intervals are unverified. - Reason for missing information: Prespecified MACE+ clinical-importance criteria and direct absolute effects/intervals are unverified. - Required materials and conditions: Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life - Materials to obtain first: Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life - Further research: If original importance/outcome material is supplied, record statistical estimates and criteria for clinical scope separately. - Conditions for verification: Retain the original superiority result’s scope without thresholds from other endpoints. - Why this condition is needed: A condition for separately recording original information and gaps for: Are superiority’s clinical importance and interpretation of all outcomes the same? - Application exceptions: Do not use the MACE noninferiority HR 1.40 as an efficacy-importance threshold. - Remaining uncertainty: Do not use the MACE noninferiority HR 1.40 as an efficacy-importance threshold. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M15 §15.3.1–15.3.3; our own application / M03 §3.2.4; our own boundary on extensions - Related sources: R01 ### N27 · Is the CAMELLIA one-year weight response an event effect? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: CAMELLIA at least 5% weight loss at one year was 38.7% versus 17.4%, P<0.001. The sibling response sheet preserves this response, a different question from the selected cardiovascular event superiority. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis denominators and intervals for weight response are unverified. - Reason for missing information: Actual endpoint-specific analysis denominators and intervals for weight response are unverified. - Required materials and conditions: Boundaries between weight-response definitions, denominators/time points and direct event results - Materials to obtain first: Boundaries between weight-response definitions, denominators/time points and direct event results - Further research: If original results are added, record weight and direct cardiovascular outcomes separately. - Conditions for verification: Preserve sibling context without adding it as new questions or trials. - Why this condition is needed: A condition for separately recording original information and gaps for: Is the CAMELLIA one-year weight response an event effect? - Application exceptions: Do not transfer positive weight response as MACE+ superiority or a selected subclaim score. - Remaining uncertainty: Do not transfer positive weight response as MACE+ superiority or a selected subclaim score. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design - Related sources: R01 ### N28 · Are BLOOM weight response and retention separate context? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: BLOOM randomized 3,182 participants; at least 5% loss at 52 weeks was 47.5% versus 20.3%, with one-year retention of 55.4% (883/1595) versus 45.1% (716/1587). This is original weight context. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original BLOOM registration field is not applicable; actual registration information and cardiovascular superiority material are unverified. - Reason for missing information: The original BLOOM registration field is not applicable; actual registration information and cardiovascular superiority material are unverified. - Required materials and conditions: BLOOM actual analysis denominators, missing data/retention and registration information - Materials to obtain first: BLOOM actual analysis denominators, missing data/retention and registration information - Further research: If original BLOOM material is supplied, link weight results and denominators/retention only to that trial. - Conditions for verification: Retain the boundary between a separate weight trial and selected cardiovascular results. - Why this condition is needed: A condition for separately recording original information and gaps for: Are BLOOM weight response and retention separate context? - Application exceptions: Do not repurpose BLOOM weight/retention values as CAMELLIA events or attrition. - Remaining uncertainty: Do not repurpose BLOOM weight/retention values as CAMELLIA events or attrition. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary - Related sources: R03 ### N29 · What were the maintenance trial’s 24-week and 52-week results? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The maintenance trial concerns 137 participants who lost at least 5% with a low-calorie diet. At 24 weeks, at least 5% maintenance was 73.9% versus 57.4% (P=.033), with additional −2.4±0.8 kg versus +0.6±0.8 kg (P=.010); neither 52-week co-primary result showed a between-group difference. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Quantitative 52-week effects/intervals, each analysis denominator, the meaning of ± and actual registration information are unverified. - Reason for missing information: Quantitative 52-week effects/intervals, each analysis denominator, the meaning of ± and actual registration information are unverified. - Required materials and conditions: Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans - Materials to obtain first: Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans - Further research: If original maintenance material is supplied, record time points, co-primary endpoints, denominators and uncertainty. - Conditions for verification: Preserve original maintenance results and time-specific gaps separately. - Why this condition is needed: A condition for separately recording original information and gaps for: What were the maintenance trial’s 24-week and 52-week results? - Application exceptions: Do not transfer a 24-week signal as 52-week weight maintenance or CAMELLIA cardiovascular events. - Remaining uncertainty: Do not transfer a 24-week signal as 52-week weight maintenance or CAMELLIA cardiovascular events. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4; Chamgap extension boundary - Related sources: R04 ### N30 · What is the extension scope from weight/maintenance to long-term clinical events? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The parent describes weight as a surrogate for clinical events and maintenance results as inconsistent. Cardiovascular superiority is a separate direct MACE+ result. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Long-term clinical benefit and effects after discontinuation that cannot be explained by weight results are unverified. - Reason for missing information: Long-term clinical benefit and effects after discontinuation that cannot be explained by weight results are unverified. - Required materials and conditions: Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation - Materials to obtain first: Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation - Further research: If direct long-term results are supplied, separate trials/time points and surrogates/clinical events. - Conditions for verification: Preserve the different outcomes of weight signals and direct cardiovascular events. - Why this condition is needed: A condition for separately recording original information and gaps for: What is the extension scope from weight/maintenance to long-term clinical events? - Application exceptions: Do not automatically extend weight loss to improved long-term events, mortality or quality of life. - Remaining uncertainty: Do not automatically extend weight loss to improved long-term events, mortality or quality of life. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design / M03 §3.2.4; Chamgap extension boundary - Related sources: R01, R03, R04 ### N31 · What is the original history of the developer program and independent replication? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary states that BLOOM and CAMELLIA share a developer program with overlapping funding and authors, are not independent replication by different research teams/funders, and retain R1. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current unique-trial counts and exhaustive lists of independent families are not established. - Reason for missing information: Current unique-trial counts and exhaustive lists of independent families are not established. - Required materials and conditions: Original lists of report/developer/author/funding relationships and independent material - Materials to obtain first: Original lists of report/developer/author/funding relationships and independent material - Further research: If relevant material is supplied, distinguish clinical-trial families from funding/author independence. - Conditions for verification: Preserve original nonindependent-program history without new independence certification. - Why this condition is needed: A condition for separately recording original information and gaps for: What is the original history of the developer program and independent replication? - Application exceptions: Do not calculate independent-replication counts from separate trial/citation counts or regulatory reviews. - Remaining uncertainty: Do not calculate independent-replication counts from separate trial/citation counts or regulatory reviews. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items / M04 §4.6.1–4.6.2, M15 §15.3.1; Chamgap adaptation - Related sources: R01, R03 ### N32 · In which material context do the original FDA cancer-reanalysis results belong? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary’s FDA reanalysis of completed data describes 462 people diagnosed with cancer (7.7%, 520 primary cancers) versus 423 (7.1%, 470 cancers), with pancreatic, colorectal and lung cancer imbalances contributing. It concerns safety in the same CAMELLIA trial. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original regulatory material and cancer-collection/adjudication details remain unread. - Reason for missing information: Original regulatory material and cancer-collection/adjudication details remain unread. - Required materials and conditions: Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results - Materials to obtain first: Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results - Further research: If original regulatory material is supplied, record the decision at the time, clinical aggregation and direct content separately. - Conditions for verification: Preserve the original FDA summary as regulatory/safety context. - Why this condition is needed: A condition for separately recording original information and gaps for: In which material context do the original FDA cancer-reanalysis results belong? - Application exceptions: Do not turn regulatory reanalysis into a separate efficacy trial, new participants or directly read paper results. - Remaining uncertainty: Do not turn regulatory reanalysis into a separate efficacy trial, new participants or directly read paper results. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design - Related sources: R05 ### N33 · Are people diagnosed with cancer and primary-cancer counts distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Cancer diagnoses involved 462 versus 423 people, while primary-cancer counts were 520 versus 470: different units. The context is the same 12,000-participant CAMELLIA trial. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Multiple-primary-cancer handling, follow-up/analysis denominators and cancer-type-specific values are unverified. - Reason for missing information: Multiple-primary-cancer handling, follow-up/analysis denominators and cancer-type-specific values are unverified. - Required materials and conditions: People/primary cancers/overlap/duration and at-risk population denominators - Materials to obtain first: People/primary cancers/overlap/duration and at-risk population denominators - Further research: If original cancer-aggregation tables are supplied, link units and observation periods for people and multiple primary cancers. - Conditions for verification: Keep original people, counts and percentages separated and unchanged. - Why this condition is needed: A condition for separately recording original information and gaps for: Are people diagnosed with cancer and primary-cancer counts distinguished? - Application exceptions: Do not add people with cancer and cancer counts or back-calculate duplicate people. - Remaining uncertainty: Do not add people with cancer and cancer counts or back-calculate duplicate people. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation - Related sources: R05 ### N34 · Is one additional cancer per 470 patient-years the original estimate? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original FDA summary of approximately one additional cancer per 470 patient-years of treatment and a widening difference over time is preserved. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original estimation methods, time-specific tables and cumulative-exposure denominators are unverified. - Reason for missing information: Original estimation methods, time-specific tables and cumulative-exposure denominators are unverified. - Required materials and conditions: Patient-year estimation method, observation windows and time-specific cancer/exposure denominators - Materials to obtain first: Patient-year estimation method, observation windows and time-specific cancer/exposure denominators - Further research: If original time/analysis material is supplied, record the estimate’s observation scope and denominator. - Conditions for verification: Retain time/units and estimation limitations in the original regulatory summary. - Why this condition is needed: A condition for separately recording original information and gaps for: Is one additional cancer per 470 patient-years the original estimate? - Application exceptions: Do not convert the original 470 patient-years value to individual risk, a new NNH or back-calculated events. - Remaining uncertainty: Do not convert the original 470 patient-years value to individual risk, a new NNH or back-calculated events. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M19 §19.2 design-specific harm questions; temporal-relationship details are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; Chamgap adaptation - Related sources: R05 ### N35 · Are regulatory cancer decisions and statistical confirmation distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary explicitly states that the public FDA safety communication lacked overall-cancer HR, CI and P values, and distinguishes regulatory judgment from statistically confirmed overall-cancer harm. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct material on overall-cancer HR, CI, P values and prespecified clinical thresholds remains unread. - Reason for missing information: Direct material on overall-cancer HR, CI, P values and prespecified clinical thresholds remains unread. - Required materials and conditions: Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds - Materials to obtain first: Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds - Further research: If original statistical/regulatory material is supplied, record original decisions, estimates and uncertainty separately. - Conditions for verification: Distinguish original regulatory judgments from gaps in direct statistical material. - Why this condition is needed: A condition for separately recording original information and gaps for: Are regulatory cancer decisions and statistical confirmation distinguished? - Application exceptions: Do not calculate or invent new cancer HRs/CIs/P values, statistical significance or causal certification. - Remaining uncertainty: Do not calculate or invent new cancer HRs/CIs/P values, statistical significance or causal certification. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design - Related sources: R05 ### N36 · What are the original date and scope of the market-withdrawal record? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original summary records the FDA request for voluntary withdrawal on February 13, 2020 and Eisai’s US market withdrawal in 2020. “No longer marketed” is also original wording from the existing reference date. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current marketing/authorization status was not externally looked up in this production. - Reason for missing information: Current marketing/authorization status was not externally looked up in this production. - Required materials and conditions: Original FDA communication, withdrawal date/region and separate update scope for current product status - Materials to obtain first: Original FDA communication, withdrawal date/region and separate update scope for current product status - Further research: If actual status material is supplied, record withdrawal at the time and verification of current status as separate events. - Conditions for verification: Retain original dates and US withdrawal alongside the scope not currently looked up. - Why this condition is needed: A condition for separately recording original information and gaps for: What are the original date and scope of the market-withdrawal record? - Application exceptions: Do not promote original historical status to a completed current authorization/marketing lookup. - Remaining uncertainty: Do not promote original historical status to a completed current authorization/marketing lookup. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool - Related sources: R05 ### N37 · Does cardiovascular noninferiority substitute for cancer or overall safety? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original counterview explicitly states that cardiovascular noninferiority does not substitute for cancer safety. The parent safety warning is preserved as original history. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Details of all harms and other safety endpoints are unverified. - Reason for missing information: Details of all harms and other safety endpoints are unverified. - Required materials and conditions: Endpoint-specific safety results, harm collection and scope of decisions - Materials to obtain first: Endpoint-specific safety results, harm collection and scope of decisions - Further research: If harm material is supplied, record cardiovascular safety, cancer signals and other harms as separate endpoints. - Conditions for verification: Separate endpoint-specific safety scope and other long-term harms. - Why this condition is needed: A condition for separately recording original information and gaps for: Does cardiovascular noninferiority substitute for cancer or overall safety? - Application exceptions: Do not convert meeting MACE noninferiority to absence of all harms or permission to take the drug. - Remaining uncertainty: Do not convert meeting MACE noninferiority to absence of all harms or permission to take the drug. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; Chamgap adaptation / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation - Related sources: R01, R05 ### N38 · Are harm collection, discontinuation and missing follow-up verified? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: Cancer reanalysis and a safety warning appear in the original summary, but there are no arm-specific tables of systematic/spontaneous harm collection, severity or discontinuation/attrition. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Harm-collection methods, discontinuation/missing data and disclosure scope for all events are unverified. - Reason for missing information: Harm-collection methods, discontinuation/missing data and disclosure scope for all events are unverified. - Required materials and conditions: All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up - Materials to obtain first: All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up - Further research: If original safety flow/tables are supplied, distinguish event collection, unreported results and unread material. - Conditions for verification: Distinguish currently unread material from confirmation that original results were unreported. - Why this condition is needed: A condition for separately recording original information and gaps for: Are harm collection, discontinuation and missing follow-up verified? - Application exceptions: Do not label a safety summary’s presence as complete collection of all harms or zero events. - Remaining uncertainty: Do not label a safety summary’s presence as complete collection of all harms or zero events. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design / M19 §19.1.2–19.2.4, M04 §4.6.3; Chamgap adaptation / M08 §8.2.2, M15 §15.3.1; Chamgap adaptation - Related sources: R01, R05 ### N39 · What are alternative harm causes and long-term/rare harms or vulnerable populations? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The original summary includes cancer imbalance over time, but lacks direct analyses of baseline cancer risk, concurrent treatment and particular populations or rare harms. - Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct material on alternative causes, subgroups, rare harms and other long-term harms is unverified. - Reason for missing information: Direct material on alternative causes, subgroups, rare harms and other long-term harms is unverified. - Required materials and conditions: Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations - Materials to obtain first: Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations - Further research: If original long-term/population-specific material is supplied, distinguish original observations from gaps for other populations and rare harms. - Conditions for verification: Distinguish original signals from unverified alternatives or extension scope. - Why this condition is needed: A condition for separately recording original information and gaps for: What are alternative harm causes and long-term/rare harms or vulnerable populations? - Application exceptions: Do not establish a regulatory signal as causality or risk magnitude for all participants, exposures or the class. - Remaining uncertainty: Do not establish a regulatory signal as causality or risk magnitude for all participants, exposures or the class. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M19 §19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design - Related sources: R05 ### N40 · Are harm records from regulatory reanalysis, a paper and a communication independent replication? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original trial and FDA reanalysis concern the same CAMELLIA population; the related review paper and communication also refer to that trial. They are not added as new independent harm trials. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Independent harm replication and aggregation of new unique events are not established. - Reason for missing information: Independent harm replication and aggregation of new unique events are not established. - Required materials and conditions: Aggregation relationships among original material/re-citations, reviews, communications and papers - Materials to obtain first: Aggregation relationships among original material/re-citations, reviews, communications and papers - Further research: If relevant original documents are supplied, record identity and event relationships between reanalysis and independent material. - Conditions for verification: Preserve relationships between document slots and the original population. - Why this condition is needed: A condition for separately recording original information and gaps for: Are harm records from regulatory reanalysis, a paper and a communication independent replication? - Application exceptions: Do not count three documents, the same registration and the same cancer records as three independent populations. - Remaining uncertainty: Do not count three documents, the same registration and the same cancer records as three independent populations. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.6.1–4.6.2; harm-material adaptations are Chamgap designs / M04 §4.6.1–4.6.2 on distinguishing studies from reports; cohort and outcome connections are Chamgap adaptations - Related sources: R01, R02, R05 ### N41 · At what level are each report’s funding, author and operational roles recorded? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: CAMELLIA was fully funded by Eisai, with sponsor co-design/manuscript participation and company-affiliated authors. BLOOM is described as sharing a developer program and overlapping funding/authors. The maintenance-trial funding value is “reported in the original text”. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The maintenance trial’s specific sponsor and complete COI/data access for each report are unverified. - Reason for missing information: The maintenance trial’s specific sponsor and complete COI/data access for each report are unverified. - Required materials and conditions: Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures - Materials to obtain first: Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures - Further research: If original disclosures are supplied, record funding and operational/author roles for each report. - Conditions for verification: Retain original report-specific roles/funding descriptions and gaps separately. - Why this condition is needed: A condition for separately recording original information and gaps for: At what level are each report’s funding, author and operational roles recorded? - Application exceptions: Do not convert “reported in the original text” to full-text reading in this production or establishment of a specific sponsor. - Remaining uncertainty: Do not convert “reported in the original text” to full-text reading in this production or establishment of a specific sponsor. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: CHAMGAP's own independence and attribution conditions. Official methodological sections used in this pilot do not guarantee every detail of this item / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application - Related sources: R01, R03, R04 ### N42 · How much of the FDA review paper was actually read? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: A citation exists for Sharretts et al., PMID 32905671, and its original flag is “no abstract; do not guess content”. The external paper was not read in this production. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The paper’s own content, direct results and disclosures remain unread. - Reason for missing information: The paper’s own content, direct results and disclosures remain unread. - Required materials and conditions: Paper full text, citation/review context and original conflict-of-interest disclosures - Materials to obtain first: Paper full text, citation/review context and original conflict-of-interest disclosures - Further research: If the user supplies the original full text, record material actually read separately from the FDA communication/summary. - Conditions for verification: Retain original citation/no-abstract labels and unread status. - Why this condition is needed: A condition for separately recording original information and gaps for: How much of the FDA review paper was actually read? - Application exceptions: Do not claim FDA communication values were directly read in the paper because its title mentions the same trial. - Remaining uncertainty: Do not claim FDA communication values were directly read in the paper because its title mentions the same trial. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and the hyperlink contract are Chamgap design / M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items - Related sources: R02 ### N43 · Is extension to other weight-loss drugs or the class avoided? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original advertising discussion explains distinct withdrawal reasons: fenfluramine valvulopathy, sibutramine cardiovascular harms and rimonabant psychiatric harms. These are not direct lorcaserin cardiovascular-superiority material. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct event effects and comparative harms of other products/classes are outside this material’s scope. - Reason for missing information: Direct event effects and comparative harms of other products/classes are outside this material’s scope. - Required materials and conditions: Direct product/mechanism/harm-specific material and comparison scope - Materials to obtain first: Direct product/mechanism/harm-specific material and comparison scope - Further research: If material for a separate question is supplied, write each product’s original context separately. - Conditions for verification: Retain original extension limitations and do not mix results from other products. - Why this condition is needed: A condition for separately recording original information and gaps for: Is extension to other weight-loss drugs or the class avoided? - Application exceptions: Do not apply lorcaserin results to other products or the whole class, or create new treatment-selection instructions. - Remaining uncertainty: Do not apply lorcaserin results to other products or the whole class, or create new treatment-selection instructions. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap design / M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool - Related sources: R01 ### N44 · Are the reference date, corrections, Korean/English text and empty-value history preserved? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The reference date 2026-08-26, empty corrections array, empty deliberation string, Korean/English text and null/false/empty-string parent-axis values are preserved. Historical marketing/verdict wording is not new current verification. - Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Separate evidence-cutoff/facets keys are absent, and no external latest correction, withdrawal or authorization-status lookup was performed. - Reason for missing information: Separate evidence-cutoff/facets keys are absent, and no external latest correction, withdrawal or authorization-status lookup was performed. - Required materials and conditions: Original dates, corrections, current update scope and original empty values - Materials to obtain first: Original dates, corrections, current update scope and original empty values - Further research: If actual update material is supplied, distinguish the original version and a new correction event. - Conditions for verification: Link original languages, dates and empty values with the actual current reading scope. - Why this condition is needed: A condition for separately recording original information and gaps for: Are the reference date, corrections, Korean/English text and empty-value history preserved? - Application exceptions: Do not borrow the existing reference date as a current review date or convert an empty corrections array to certification that no corrections exist anywhere. - Remaining uncertainty: Do not borrow the existing reference date as a current review date or convert an empty corrections array to certification that no corrections exist anywhere. Review of the existing content remains incomplete, and external originals were not checked. - Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design - Related sources: R01, R02, R03, R04, R05 ## Evidence and sources ### R01 Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018;379:1107-1117. PMID: 30145941. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30145941/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: MACE+: 707 participants (11.8%) versus 727 (12.1%), HR 0.97 (0.87~1.07), P=.55; separate MACE: 364 participants (6.1%) versus 369 (6.2%), HR 0.99 (95% CI 0.85~1.14), with original wording that the HR 1.40 noninferiority margin was met. One-year weight response is separate context. Record level: Not recorded Independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored summary | Local preserved copy | Local preserved summary acquired | Summary read | The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread. | | External abstract | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | External abstract slot preserving the original source link; no current access, reading or link verification was performed. | | External full text | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original source link connects identity/material and does not mean direct full-text acquisition or current content reading. | | External registration | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Only the original NCT02019264 string is preserved; registration content, timing and prespecified definitions remain unread. | | Required material: protocol/review methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Required scope: MACE/MACE+ definitions, testing hierarchy, models, denominators/follow-up, harms and funding roles; existence, availability and acquisition of original material are unverified. | | Required material: SAP and analysis methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread. | | Required material: outcomes, denominators, and harms | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Details of this material’s MACE/MACE+ definitions, testing hierarchy, models, denominators/follow-up, harms and funding roles are needed. Results or denominators from other reports are not copied. | | Required materials: funding and COI | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures. | ### R02 Sharretts J, Galescu O, Gomatam S, et al. Cancer Risk Associated with Lorcaserin—The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383:1000-1002. PMID: 32905671. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32905671/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: The preserved citation records that a paper summarizing the FDA CAMELLIA review exists. Its original “no abstract; do not guess content” flag is retained. Direct paper results remain unread; FDA communication values are not attributed as directly read paper content. Record level: Not recorded Independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored summary | Local preserved copy | Local preserved summary acquired | Summary read | Only citation entry 1 and the existence of the related citation in the stored summary were read. The no-abstract/do-not-guess labels were retained and direct paper content was not created. | | External abstract | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original flag is no abstract. This is an existing record; no current access occurred and paper content was not guessed. | | External full text | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original source link connects identity/material and does not mean direct full-text acquisition or current content reading. | | External registration | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | This citation has no direct registration field; its mention of the same trial in the title is not used to fill a report-specific NCT field. | | Required material: protocol/review methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Required scope: paper full text, original disclosures, actual review content and relationships with the communication/summary; existence, availability and acquisition of original material are unverified. | | Required material: SAP and analysis methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread. | | Required material: outcomes, denominators, and harms | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Details of this material’s paper full text, original disclosures, actual review content and relationships with the communication/summary are needed. Results or denominators from other reports are not copied. | | Required materials: funding and COI | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures. | ### R03 Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010. PMID: 20647200. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20647200/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: 3,182 randomized participants; at least 5% loss at 52 weeks: 47.5% versus 20.3%; one-year retention: 55.4% (883/1595) versus 45.1% (716/1587). These are not repurposed as direct results for selected cardiovascular superiority. Record level: Not recorded Independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored summary | Local preserved copy | Local preserved summary acquired | Summary read | The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread. | | External abstract | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | External abstract slot preserving the original source link; no current access, reading or link verification was performed. | | External full text | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original source link connects identity/material and does not mean direct full-text acquisition or current content reading. | | External registration | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original registration-identifier value “not applicable” is preserved unchanged; actual registration information and content are unverified. | | Required material: protocol/review methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Required scope: weight-analysis/retention denominators, missing data, registration and funding/author relationships; existence, availability and acquisition of original material are unverified. | | Required material: SAP and analysis methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread. | | Required material: outcomes, denominators, and harms | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Details of this material’s weight-analysis/retention denominators, missing data, registration and funding/author relationships are needed. Results or denominators from other reports are not copied. | | Required materials: funding and COI | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures. | ### R04 Wadden TA, Walsh OA, Berkowitz RI, et al. A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss…. PMID: 29288545. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29288545/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: Maintenance trial of 137 participants who lost at least 5% with a low-calorie diet; at 24 weeks: 73.9% versus 57.4% (P=.033), −2.4±0.8 kg versus +0.6±0.8 kg (P=.010); neither 52-week co-primary result showed a between-group difference. Not direct cardiovascular-event results. Record level: Not recorded Independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored summary | Local preserved copy | Local preserved summary acquired | Summary read | The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread. | | External abstract | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | External abstract slot preserving the original source link; no current access, reading or link verification was performed. | | External full text | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original source link connects identity/material and does not mean direct full-text acquisition or current content reading. | | External registration | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original registration-identifier value “not applicable” is preserved unchanged; actual registration information and content are unverified. | | Required material: protocol/review methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Required scope: time-specific co-primary outcomes/denominators, meaning of ±, 52-week intervals, plans and registration/funding; existence, availability and acquisition of original material are unverified. | | Required material: SAP and analysis methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread. | | Required material: outcomes, denominators, and harms | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Details of this material’s time-specific co-primary outcomes/denominators, meaning of ±, 52-week intervals, plans and registration/funding are needed. Results or denominators from other reports are not copied. | | Required materials: funding and COI | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures. | ### R05 US Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. February 13, 2020. [Official source](https://www.fda.gov/media/135189/download) Materials actually read: Summary read; external materials not read Findings recorded in the summary: Cancer reanalysis of the same CAMELLIA trial: 462 people diagnosed with cancer (7.7%, 520 primary cancers) versus 423 (7.1%, 470 cancers); approximately one additional cancer per 470 patient-years, with a widening difference over time. The 2020-02-13 FDA request and Eisai US withdrawal are original history; no current communication/marketing lookup was performed. Record level: Not recorded Independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored summary | Local preserved copy | Local preserved summary acquired | Summary read | The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread. | | External communication content | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | External FDA communication summary/content slot. It is not a PubMed paper abstract, and no current access or reading occurred. | | External original communication | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | The original source link connects identity/material and does not mean direct full-text acquisition or current content reading. | | External registration | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Only the original NCT02019264 string is preserved; registration content, timing and prespecified definitions remain unread. | | Required material: protocol/review methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Required scope: original communication/regulatory text, cancer definitions/collection, people/cancer/time denominators and original judgments/uncertainty; existence, availability and acquisition of original material are unverified. | | Required material: SAP and analysis methods | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread. | | Required material: outcomes, denominators, and harms | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Details of this material’s original communication/regulatory text, cancer definitions/collection, people/cancer/time denominators and original judgments/uncertainty are needed. Results or denominators from other reports are not copied. | | Required materials: funding and COI | Current public availability and detailed existence remain unverified | Access not attempted; not obtained | Not read | Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures. | ## Review criteria and methods These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score. - M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work. - M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work. - M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work. - M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work. - M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work. ## What the statuses mean - Met: The original content has been reviewed as meeting the conditions. This status is not used in this preparation. - Partly verified: Some information in the stored summary was linked during preparation; clinical verification or review is not complete. - Unverified: Required direct values, definitions or materials have not been established within the current storage and reading scope. This does not mean zero effect, no papers or failed access. - Review incomplete: Review of existing content or actual review incomplete. - Not reported: Used only when original materials were actually read and the outcome was judged unreported. Not used for external materials unread in this work. - Inaccessible: Used only when an actual access attempt has a recorded failure. Not used for access that was not attempted in this work. - Insufficient evidence for the conditions: Indicates insufficient direct materials for the relevant scope or conditions; it is not a new grade. - Not applicable: Used when the reason it does not apply to the original question is stated. - Conflicting data: Retains the scope of conflicting statements in original materials; it is not an arbitrary reassessment. ## Change history 2026-10-11 · Public page/materials 1.0. A public view and materials were prepared from the existing 44 items. No new clinical search, verification-status change or scoring was performed.